Steven Cohen’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Steven Cohen’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-30,000	Closed	-$3.47M	–	3024
2023 Q3	$3.47M	Sell	30,000 -10,000	-25%	-$1.07M	0.01%	997
2023 Q2	$4.11M	Buy	+40,000	New	+$4.22M	0.01%	871
2017 Q4	–	Sell	-500,000	Closed	-$6.34M	–	1187
2017 Q3	$6.34M	Buy	+500,000	New	+$6.36M	0.03%	499

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Steven Cohen's HZNP Position: Q4 2023 in Review

Steven Cohen sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 175,000 shares — an estimated $20.2M sold.

Steven Cohen first reported a position in HZNP in Q3 2014 and held it in 21 quarters. The position peaked at $130M in Q3 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Steven Cohen reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Steven Cohen sold 175,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $20.2M.
Steven Cohen first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014 and held it in 21 quarters.
Steven Cohen's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $130M in Q3 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.